|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 2900 Ames Crossing Road |
Address2 |
|
City | Eagan |
State | MN |
Zip Code | 55121 |
Country | USA |
3. Principal place of business (if different than line 2)
City | Eagan |
State | MN |
Zip Code | 55121 |
Country | USA |
|
5. Senate ID# 400339576-12
|
||||||||
|
6. House ID# 403630000
|
TYPE OF REPORT | 8. Year | 2024 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: David Root |
Date | 4/22/2024 1:48:43 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
S.1339: "Pharmacy Benefit Manager Reform Act," provisions related to disclosure, audits and PBM contracting. Proposed amendments to S.1339 creating a default spread pricing option with options to elect pass-through payments for PBM compensation. S.3548: "Health Care Prices Revealed and Information to Consumers Explained Transparency Act," a bill to amend the Public Health Services Act to provide for hospital and insurer price transparency. H.R.5378: "Lower Costs, More Transparency Act," provisions related to PBM transparency and disclosure requirements. S.1542/H.R.6283: "The Delinking Revenue from Unfair Gouging (DRUG) Act," provisions dictating PBM contracting terms. S.127: Pharmacy Benefit Manager Transparency Act of 2023, a bill to prevent unfair and deceptive acts or practices and the dissemination of false information related to pharmacy benefit management services for prescription drugs, and for other purposes.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Julie |
Cantor-Weinberg |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
S.3430: "Better Mental Healthcare, Lower Cost Drugs & Extenders Act," provisions related to PBMs and pharmacy contracting. S.2973: "Modernizing and Ensuring PBM Accountability Act," provisions related to PBM contracting, audits and disclosures. H.R.5526: "Seniors Access to Critical Medications Act of 2023," provisions clarifying Medicare so that delivery of medicines through various methods or by allowing a family member or caregiver to pick up medication on behalf of a patient does not violate the Stark Law and does fall within the scope of Stark's IOAS exception. H.R.7512: "Real-Time Benefit Tool Implementation Act," legislation to ensure implementation of real-time benefit tools under part D of the Medicare program. Implementation of Center for Medicare and Medicaid Services Final Rule, Contract Year 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Programs Final Rule, CMS-4192-F, CMS-1744-F, provisions related to changes in Pharmacy Direct and Indirect Renumeration. Implementation of H.R. 5376 (117th Congress)/P.L. 117-169 "The Inflation Reduction Act," provisions related to changes in Medicare Part D and government negotiation of drug prices. S.2305: "Biosimilars Red Tape Elimination Act," provisions relating improving the requirements for making a determination of interchangeability of a biological product and its reference product.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Julie |
Cantor-Weinberg |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
Lobbyist Name | Description of Offense(s) |